InSitu Biologics
Kevin Barrett joined InSitu Biologics in October 2019 as Chief Operating Officer. Before joining InSitu, Kevin held Director positions in International and Program Management for Cardiovascular Systems Inc., a medical device company focused on developing and commercializing innovative solutions for treating coronary and peripheral artery disease. In addition, Kevin has served as Director of Operations for Angioslide Inc., a medical product company in the peripheral angioplasty space with a unique product that combines PTA balloon intervention with debris capture and removal.
Kevin holds an M.B.A. from the Carlson School of Management at the University of Minnesota and a B.A. in Business from the University of St. Thomas.
This person is not in any offices
InSitu Biologics
InSitu Biologics is an emerging biotech company focused on the development of a multi-phase prolonged-release drug delivery platform for localized treatment of pain, cancer, and infection.